Literature DB >> 33798630

miR-770-5p regulates EMT and invasion in TNBC cells by targeting DNMT3A.

Senem Noyan1, Ayşe Andac Ozketen2, Hakan Gurdal3, Bala Gur Dedeoglu4.   

Abstract

MicroRNAs (miRNAs) are shown to regulate various processes in cancer like motility and invasion that are key features of the metastatic triple negative breast cancer (TNBCs). Epithelial-mesenchymal transition (EMT) is one of the well-defined cellular transitioning processes characterized with reduced E-cadherin expression and increased mesenchymal molecules such as Vimentin or Snail thereby gives the cells mobility and invasive character. Aberrant DNA methylation by DNA methyltransferases (DNMTs) plays an important role in carcinogenesis. It is well known that DNMTs are required for transcriptional silencing of tumor-associated genes. DNMT3A-induced promoter hypermethylation of E-cadherin has also been known to improve cancer metastasis. Our results indicated that miR-770-5p could downregulate Vimentin and Snail expression levels, while increasing or restoring the expression of E-Cadherin hence, leading to inhibition of EMT phenotypes along with motility and invasion. Specifically, we showed that overexpression of miR-770-5p restored the expression of E-Cadherin in MDA-MB-231 cells via directly targeting DNMT3A. We also observed the change in the spindled shapes showing the loss of mesenchymal characteristics and gain of epithelial phenotype in miR-770-5p overexpressing cells. When considered together, our results show that miR-770-5p could effectively inhibit invasion potential driven by EMT.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Epithelial-mesenchymal transition (EMT); Motility and invasion; TNBC; miR-770-5p

Mesh:

Substances:

Year:  2021        PMID: 33798630     DOI: 10.1016/j.cellsig.2021.109996

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  2 in total

1.  Concise Synthesis of Tunicamycin V and Discovery of a Cytostatic DPAGT1 Inhibitor.

Authors:  Katsuhiko Mitachi; David Mingle; Wendy Effah; Antonio Sánchez-Ruiz; Kirk E Hevener; Ramesh Narayanan; William M Clemons; Francisco Sarabia; Michio Kurosu
Journal:  Angew Chem Int Ed Engl       Date:  2022-06-10       Impact factor: 16.823

Review 2.  DNMT3A and DNMT3B in Breast Tumorigenesis and Potential Therapy.

Authors:  Xiaxia Man; Qi Li; Baogang Wang; He Zhang; Songling Zhang; Ziyi Li
Journal:  Front Cell Dev Biol       Date:  2022-05-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.